Congenital TTP: Case Report and Literature Review
Open Access
Abstract
Background: Congenital thrombotic thrombocytopenic purpura (cTTP) is an extremely rare disease caused by an inherited deficiency of ADAMTS13. Residual ADAMTS13 activity ADAMTS13 gene. Daily fresh frozen plasma (FFP) infusions normalized platelet counts and hemolysis indices. Prophylactic plasma infusions were scheduled every 21 days. Despite prophylaxis, the child experienced multiple disease relapses after infectious episodes, requiring hospitalization and daily plasma infusions, sometimes complicated by infection or thrombosis related to venous access. Following ethics committee approval, recombinant ADAMTS13 was administered at 40 IU/kg every two weeks. After one year of treatment, the child experienced no disease recurrence and no infusion-related adverse events. No anti-ADAMTS13 antibodies were detected. Discussion: cTTP is a very rare disease, often misdiagnosed, with high neonatal mortality. Children frequently experience recurrent TTP triggered by infections. Prophylactic ADAMTS13 replacement should be considered to reduce disease recurrence. Recombinant ADAMTS13 appears to be a promising, effective, and safe therapeutic option.Keywords
Funding Information
- Italian Ministry of Health
- Italian Ministry of Education and Research—MUR
This publication has 18 references indexed in Scilit:
- Genetics of thrombotic thrombocytopenic purpura: systematic review in immune and congenital thrombotic thrombocytopenic purpuraJournal of Thrombosis and Haemostasis, 2026
- 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpuraJournal of Thrombosis and Haemostasis, 2025
- Real-world safety and efficacy of rADAMTS13 in the treatment of congenital thrombotic thrombocytopenic purpura in pediatric patients in PolandJournal of Thrombosis and Haemostasis, 2024
- Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 2024
- Hereditary Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 2019
- Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpuraJournal of Thrombosis and Haemostasis, 2018
- ADAMTS13 Gene Mutations Influence ADAMTS13 Conformation and Disease Age-Onset in the French Cohort of Upshaw–Schulman SyndromeThrombosis and Haemostasis, 2018
- Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpuraAmerican Journal of Hematology, 2014
- A phenotype–genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United KingdomJournal of Thrombosis and Haemostasis, 2012
- Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpuraNature, 2001